{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T03:20:19Z","timestamp":1767151219749,"version":"build-2238731810"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1038\/s41375-025-02567-w","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T04:25:08Z","timestamp":1742790308000},"page":"988-990","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Correlation of progression-free survival and overall survival after treatment for relapsed Hodgkin lymphoma: individual patient data analysis of randomized German Hodgkin Study Group (GHSG) Trials"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9662-9900","authenticated-orcid":false,"given":"P. J.","family":"Br\u00f6ckelmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1927-3514","authenticated-orcid":false,"given":"D. A.","family":"Eichenauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6662-6864","authenticated-orcid":false,"given":"S.","family":"Borchmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. S.","family":"Robertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Behringer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Welters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3481-7997","authenticated-orcid":false,"given":"J.","family":"Ferdinandus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"B\u00f6ll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5680-8714","authenticated-orcid":false,"given":"H.","family":"Tharmaseelan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2909-0826","authenticated-orcid":false,"given":"C.","family":"Kobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. -T.","family":"Eich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Baues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7208-4117","authenticated-orcid":false,"given":"W.","family":"Klapper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Borchmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1410-4487","authenticated-orcid":false,"given":"B.","family":"von Tresckow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"2567_CR1","unstructured":"Guideline on the clinical evaluation of anticancer medicinal products - Revision 6. European Medicines Agency; 2024."},{"key":"2567_CR2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/bjh.15566","volume":"184","author":"PJ Brockelmann","year":"2019","unstructured":"Brockelmann PJ, McMullen S, Wilson JB, Mueller K, Goring S, Stamatoullas A, et al. Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom. Br J Haematol. 2019;184:202\u201314.","journal-title":"Br J Haematol"},{"key":"2567_CR3","doi-asserted-by":"publisher","unstructured":"Br\u00f6ckelmann PJ, M\u00fcller H, Fuchs M, Gillessen S, Eichenauer DA, Borchmann S, et al. Correlation between progression-free and overall survival in patients with Hodgkin lymphoma: a comprehensive analysis of individual patient data from randomized German Hodgkin Study Group (GHSG) trials. Ann Oncol. 2024;S0923-7534:04988-3. https:\/\/doi.org\/10.1016\/j.annonc.2024.12.009. Online ahead of print.","DOI":"10.1016\/j.annonc.2024.12.009"},{"key":"2567_CR4","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41375-021-01442-8","volume":"36","author":"PJ Brockelmann","year":"2022","unstructured":"Brockelmann PJ, Muller H, Gillessen S, Yang X, Koeppel L, Pilz V, et al. Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis. Leukemia. 2022;36:772\u201380.","journal-title":"Leukemia"},{"key":"2567_CR5","first-page":"2727","volume":"141","author":"MA Spinner","year":"2023","unstructured":"Spinner MA, Sica RA, Tamaresis JS, Lu Y, Chang C, Lowsky R, et al. Improved outcomes for relapsed\/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents. Blood. 2023;141:2727\u201337.","journal-title":"Blood"},{"key":"2567_CR6","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1200\/JCO.23.00225","volume":"41","author":"M Merino","year":"2023","unstructured":"Merino M, Kasamon Y, Theoret M, Pazdur R, Kluetz P, Gormley N. Irreconcilable differences: the divorce between response rates, progression-free survival, and overall survival. J Clin Oncol. 2023;41:2706\u201312.","journal-title":"J Clin Oncol"},{"key":"2567_CR7","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial. Lancet. 2002;359:2065\u201371.","journal-title":"Lancet"},{"key":"2567_CR8","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1200\/JCO.2010.30.5771","volume":"28","author":"A Josting","year":"2010","unstructured":"Josting A, Muller H, Borchmann P, Baars JW, Metzner B, Dohner H, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin\u2019s lymphoma. J Clin Oncol. 2010;28:5074\u201380.","journal-title":"J Clin Oncol"},{"key":"2567_CR9","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/annonc\/mdx072","volume":"28","author":"PJ Brockelmann","year":"2017","unstructured":"Brockelmann PJ, Muller H, Casasnovas O, Hutchings M, von Tresckow B, Jurgens M, et al. Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma. Ann Oncol. 2017;28:1352\u20138.","journal-title":"Ann Oncol"},{"key":"2567_CR10","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1080\/01621459.1989.10478873","volume":"84","author":"LJ Wei","year":"1989","unstructured":"Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc. 1989;84:1065\u201373.","journal-title":"J Am Stat Assoc"},{"key":"2567_CR11","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/sim.8001","volume":"38","author":"EM Weber","year":"2019","unstructured":"Weber EM, Titman AC. Quantifying the association between progression-free survival and overall survival in oncology trials using Kendall\u2019s. Stat Med. 2019;38:703\u201319.","journal-title":"Stat Med"},{"key":"2567_CR12","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1080\/01621459.1993.10476372","volume":"88","author":"C Genest","year":"1993","unstructured":"Genest C, Rivest LP. Statistical-inference procedures for bivariate Archimedean Copulas. J Am Stat Assoc. 1993;88:1034\u201343.","journal-title":"J Am Stat Assoc"},{"key":"2567_CR13","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1002\/sim.5874","volume":"32","author":"M Schemper","year":"2013","unstructured":"Schemper M, Kaider A, Wakounig S, Heinze G. Estimating the correlation of bivariate failure times under censoring. Stat Med. 2013;32:4781\u201390.","journal-title":"Stat Med"},{"key":"2567_CR14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","volume":"112","author":"J Cohen","year":"1992","unstructured":"Cohen J. A power primer. Psychol Bull. 1992;112:155\u20139.","journal-title":"Psychol Bull"},{"key":"2567_CR15","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/s41416-020-0805-y","volume":"122","author":"L Belin","year":"2020","unstructured":"Belin L, Tan A, De Rycke Y, Dechartres A. Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review. Br J Cancer. 2020;122:1707\u201314.","journal-title":"Br J Cancer"}],"updated-by":[{"DOI":"10.1038\/s41375-025-02597-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T00:00:00Z","timestamp":1743292800000}}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02567-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02567-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02567-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T09:39:22Z","timestamp":1744018762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02567-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2567"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02567-w","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,24]]},"assertion":[{"value":"6 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: In this article the author\u2019s name D. A. Eichenauer. was incorrectly written as D. Eichenauer. The original article has been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2025","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41375-025-02597-4","URL":"https:\/\/doi.org\/10.1038\/s41375-025-02597-4","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PJB is and advisor or consultant for Hexal, Merck Sharp & Dohme, Need Inc., Stemline and Takeda; holds stock options in Need Inc., has received honoraria from AstraZeneca, BeiGene, BMS\/Celgene, Lilly, Merck Sharp & Dohme, Need Inc., Stemline and Takeda and reports research funding from BeiGene (Inst), BMS (Inst), Merck Sharp & Dohme (Inst) and Takeda (Inst); MF reports honoraria from BMS\/Celgene, Janssen and Takeda and he is the CEO of KARO GmbH; DAE reports honoraria from Takeda and Sanofi-Genzyme; SB reports a consultant role for Galapagos, has received honoraria from Takeda, reports travel support from Takeda and reports being founder and shareholder of Liqomics; JF reports and advisory role for Takeda Oncology and speaker fees from Roche Pharma and Takeda Oncology; BB has received honoraria and research funding from Amgen, Gilead, MSD, Miltenyi, Noscendo, Novartis, Pfizer and Takeda; WK reports research grants by Roche, Amgen, Takeda, Janssen and InCyte, all to the institution; BvT is an advisor or consultant for Allogene, Amgen, BMS\/Celgene, Cerus, Gilead Kite, Incyte, IQVIA, Janssen-Cilag, Lilly, Merck Sharp & Dohme, Miltenyi, Novartis, Noscendo, Pentixapharm, Pfizer, Pierre Fabre, Qualworld, Regeneron, Roche, Sobi, Serb and Takeda; has received honoraria from AbbVie, AstraZeneca, BMS\/Celgene, Gilead Kite, Incyte, Lilly, Janssen-Cilag, Merck Sharp & Dohme, Novartis, Roche and Takeda; reports research funding from Esteve (Inst), Merck Sharp & Dohme (Inst), Novartis (Inst), and Takeda (Inst); and reports travel support from AbbVie, AstraZeneca, Gilead Kite, Janssen-Cilag, Lilly, Merck Sharp & Dohme, Pierre Fabre, Roche, Takeda, and Novartis; is member of steering committees for Regeneron and Takeda. All other authors don\u2019t declare any potential conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}